SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Mustang Bio, Inc. MBIO NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Mustang Bio, Inc. (MBIO) is a Biotechnology company in the Healthcare sector, currently trading at $0.76. It has a SharesGrow Score of 69/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Valuation: MBIO trades at a trailing Price-to-Earnings (P/E) of -2.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.06.

Net income is $2M (loss), growing at +64%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $10M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 2.22 (strong liquidity). Debt-to-assets is 0%. Total assets: $18M.

Analyst outlook: 7 / 7 analysts rate MBIO as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

MBIO SharesGrow Score Overview

86/100

SharesGrow Score

Strong investment profile

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 100/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MBIO

MBIO trades at a trailing Price-to-Earnings (P/E) of -2.8 (S&P 500 average ~25). Forward PEG 0.06 — Peter Lynch undervalued (≤1.0). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

MBIO: +0%/yr revenue is, +64%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet MBIO: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 2.22 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

MBIO: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

Analyst outlook: 7 / 7 analysts rate MBIO as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range0.531-7

Volume34.28K

Avg Volume (30D)169.98K

Market Cap$5.77M

Beta (1Y)2.18

Share Statistics

EPS (TTM)-0.39

Shares Outstanding$49.08M

IPO Date2017-08-22

Employees6

CEOManuel Litchman

Financial Highlights & Ratios

Gross Profit$-41K

EBITDA$-2.39M

Net Income$-1.92M

Operating Income$-2.43M

Total Cash$17.27M

Net Debt$-17.27M

Total Assets$17.59M

Price / Earnings (P/E)-2

Analyst Forecast

Rating ConsensusBuy

Analysts Covering7

Buy 100% Hold 0% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Global Market

CurrencyUSD

ISINUS62818Q3020

Price Chart

MBIO

Mustang Bio, Inc. ↗ · NASDAQ Global Market

Healthcare • Biotechnology

0.53 52WK RANGE 7.00

People Also View

Kodiak Sciences Inc.

Corvus Pharmaceuticals, Inc.

Checkpoint Therapeutics, Inc.

Unicycive Therapeutics, Inc.

Fortress Biotech, Inc.

Fortress Biotech, Inc.

Adaptimmune Therapeutics plc

Achilles Therapeutics plc

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message